Denali Therapeutics Inc

DNLI · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Market Data

Price $21.43 +0.12 (+0.56%)

Market Cap$3.38B

P/E Ratio—

EPS$—

52W High$23.77

52W Low$10.57

Beta1.05

Data from Finnhub · Updated Mar 10, 2026